

# Blepharitis - Pipeline Insight, 2021

<https://marketpublishers.com/r/BE82FA546D3EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: BE82FA546D3EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Blepharitis - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Blepharitis Understanding

#### Blepharitis: Overview

Blepharitis is a common eye condition that makes your eyelids red, swollen, irritated, and itchy. It can cause crusty dandruff-like flakes on your eyelashes. Blepharitis can be uncomfortable. But it isn't contagious, and it usually doesn't cause any lasting damage to your eyes. The main treatment for blepharitis is regularly cleaning your eyelids and keeping them free of crusts. Blepharitis usually doesn't go away completely, but you can take steps to manage your symptoms. Talk to your eye doctor about what's causing your blepharitis and the best ways to manage it.

'Blepharitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blepharitis pipeline landscape is provided which includes the disease

overview and Blepharitis treatment guidelines. The assessment part of the report embraces, in depth Blepharitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blepharitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Blepharitis R&D. The therapies under development are focused on novel approaches to treat/improve Blepharitis.

## Blepharitis Emerging Drugs Chapters

This segment of the Blepharitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Blepharitis Emerging Drugs

### NCX 4251: NicOx

4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals which is being developed as the first targeted topical treatment of the eyelid margin for patients with acute exacerbations of blepharitis. The drug is in phase 2 of clinical trials for the treatment of blepharitis.

### TP-03: Tarsus Pharmaceuticals,

TP-03 (lotilaner ophthalmic solution 0.25%) is a novel therapeutic designed to target and eradicate Demodex mites. It is a potent, non-competitive antagonist of insect and arachnid GABA-Cl channels and a highly lipophilic molecule, which may promote its uptake in the oily sebum of the hair follicle where the mites reside. The company has

recently initiated a phase 3 trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis.

Further product details are provided in the report.....

### Blepharitis: Therapeutic Assessment

This segment of the report provides insights about the different Blepharitis drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Blepharitis

There are approx. 4+ key companies which are developing the therapies for Blepharitis. The companies which have their Blepharitis drug candidates in the most advanced stage, i.e. phase II include, NicOx.

#### Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Blepharitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Blepharitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blepharitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blepharitis drugs.

## Blepharitis Report Insights

Blepharitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Blepharitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Blepharitis drugs?

How many Blepharitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blepharitis?

What are the key collaborations (Industry–Industry, Industry–Academia),

Mergers and acquisitions, licensing activities related to the Blepharitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Blepharitis and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

NicOx

Tarsus Pharmaceuticals

AxeroVision

InSite Vision

### Key Products

NCX 4251

TP-03

AXR-270

ISV-305

## Contents

Introduction

Executive Summary

Blepharitis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Blepharitis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Blepharitis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Blepharitis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

TP-03: Tarsus Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

NCX 4251: NicOx

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Blepharitis Key Companies

Blepharitis Key Products

Blepharitis- Unmet Needs

Blepharitis- Market Drivers and Barriers

Blepharitis- Future Perspectives and Conclusion

Blepharitis Analyst Views

Blepharitis Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Blepharitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Blepharitis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Blepharitis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/BE82FA546D3EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE82FA546D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970